117 related articles for article (PubMed ID: 12324629)
1. Management of treatment-related toxicity in advanced ovarian cancer.
Dunton CJ
Oncologist; 2002; 7 Suppl 5():11-9. PubMed ID: 12324629
[TBL] [Abstract][Full Text] [Related]
2. Update on the role of topotecan in the treatment of recurrent ovarian cancer.
Herzog TJ
Oncologist; 2002; 7 Suppl 5():3-10. PubMed ID: 12324628
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with topotecan in relapsed ovarian cancer.
Herzog TJ
Gynecol Oncol; 2003 Sep; 90(3 Pt 2):S3-7. PubMed ID: 13129489
[TBL] [Abstract][Full Text] [Related]
4. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
6. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
7. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
Bookman MA
Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
[TBL] [Abstract][Full Text] [Related]
8. Optimal sequencing in the treatment of recurrent ovarian cancer.
Spriggs D
Gynecol Oncol; 2003 Sep; 90(3 Pt 2):S39-44. PubMed ID: 13129495
[TBL] [Abstract][Full Text] [Related]
9. Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer.
Morris R; Munkarah A
Oncologist; 2002; 7 Suppl 5():29-35. PubMed ID: 12324631
[TBL] [Abstract][Full Text] [Related]
10. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches.
Lin H; Changchien CC
Taiwan J Obstet Gynecol; 2007 Dec; 46(4):379-88. PubMed ID: 18182343
[TBL] [Abstract][Full Text] [Related]
11. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
12. Randomized single-agents trials in recurrent epithelial ovarian cancer.
Sessa C; Marsoni S
Int J Gynecol Cancer; 2005; 15 Suppl 3():247-51. PubMed ID: 16343240
[TBL] [Abstract][Full Text] [Related]
13. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of topotecan in front-line treatment of carcinoma of the ovary.
Coleman RL
Oncologist; 2002; 7 Suppl 5():46-55. PubMed ID: 12324633
[TBL] [Abstract][Full Text] [Related]
15. Relapsed ovarian cancer: challenges and management strategies for a chronic disease.
Armstrong DK
Oncologist; 2002; 7 Suppl 5():20-8. PubMed ID: 12324630
[TBL] [Abstract][Full Text] [Related]
16. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
Gordon AN; Tonda M; Sun S; Rackoff W;
Gynecol Oncol; 2004 Oct; 95(1):1-8. PubMed ID: 15385103
[TBL] [Abstract][Full Text] [Related]
18. Pros and cons for systemic therapy in recurrent ovarian cancer.
Oskay-Ozcelik G; Sehouli J
Anticancer Res; 2009 Jul; 29(7):2831-6. PubMed ID: 19596970
[TBL] [Abstract][Full Text] [Related]
19. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
20. Current concepts of treatment strategies in advanced or recurrent ovarian cancer.
Salzberg M; Thurlimann B; Bonnefois H; Fink D; Rochlitz C; von Moos R; Senn H
Oncology; 2005; 68(4-6):293-8. PubMed ID: 16020955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
